On April 13, 2021, Arcellx, a privately held clinical-stage biopharmaceutical company, announced that it raised $115 million in a Series C financing. Arcellx plans to use the financing to advance its pipeline of adaptive and controllable cell therapies. Wilson Sonsini Goodrich & Rosati is advising Arcellx in the transaction.

The Wilson Sonsini team includes partner Dan Koeppen, and associates Meghan Burton and Amanda Creedon.

Please see Arcellx’s press release for more information.